Abacavir lamivudine zidovudine has been approved in the United States and in the European Union and in the Other Countries

Studies listed may include approved and non-approved uses, formulations or treatment regimens. Before prescribing any product mentioned in this Register, healthcare Professionals should consult prescribing information approved in their country (view UK and US information for Healthcare Professionals).

The summaries are in PDF format. If you do not have Adobe® Acrobat® Reader™ installed, you can download it for free.


abacavir_lamivudine_zidovudine studies

Select the study ID number to view the trial summary

Study IDPhaseTitle
AZL40001 IV An open-label, single arm, multicentre, pilot phase IV study to evaluate the efficacy and safety of a potent combination therapy (Trizivir + Efavirenz) in antiretroviral naïve adults with a CD4+ cell count <200mm3 over a 48-week treatment period (TETRA – Trizivir Efavirenz TReAtment)
COL30336 IV A Phase IV, Open-Label, Multicenter Study of the Efficacy and Safety of Quadruple Combination Antiretroviral Therapy with COMBIVIR (Lamivudine 150mg/Zidovudine 300mg) BID, ZIAGEN (Abacavir) 300mg BID, and SUSTIVA (Efavirenz) 600mg QD for 24 Weeks, Followed by Therapy with the Triple Nucleoside Combination Tablet (Abacavir 300mg/Lamivudine 150mg/Zidovudine 300mg [TRIZIVIR]) BID plus SUSTIVA (Efavirenz) 600mg QD for 24 Weeks in HIV-Infected Adults.
COL30494 IV An Open-Label Multicentre Study to Evaluate the Adherence to, General Satisfaction and Quality of Life After 24 Weeks Therapy With a Triple Combination tablet (TRIZIVIR™) [Abacavir, Lamivudine, and Zidovudine] in HIV-1 Infected Subjects With Undetectable Plasma HIV-1 RNA Levels
ESS100327 IV A Phase IV Randomized, Multicenter, Open-Label Study to Compare the Safety, Tolerability and Efficacy of TRIZIVIR (Abacavir 300mg, Lamivudine 150mg, and Zidovudine 300mg) BID vs COMBIVIR (Lamivudine 150mg and Zidovudine 300mg) BID plus Atazanavir 400mg QD in Antiretroviral Naive HIV-1 Infected Subjects over 48 Weeks
ESS30005 IV A Phase IV, Open-Label, Multicenter Study of Treatment with TRIZIVIR (Abacavir 300mg/Lamivudine 150mg/Zidovudine 300mg) Twice Daily and Tenofovir 300 mg Once-Daily for 48 Weeks in HIV-Infected Subjects Experiencing Early Virologic Failure (ZIAGEN Intensification Protocol)
ESS40013 IV A Phase IV Multi-center Study of the Efficacy and Safety of 48-Week Induction Treatment with TRIZIVIR (Abacavir 300mg/Lamivudine 150mg/Zidovudine 300mg Combination Tablet BID) + Efavirenz (600mg QD) Followed by 48-Week Randomized, Open-Label, Maintenance Treatment with TRIZIVIR ± Efavirenz in HIV-1 Infected Antiretroviral Therapy Naïve Subjects
QUAD001 (COL30470) IV A Pilot, Randomised, Open-Label, Monocenter Study to Evaluate the Safety and Efficacy of a Quadruple Combination Therapy of Triple Combination Tablet (Trizivir) [abacavir, lamivudine, zidovudine] Plus Saquinavir-SGC/Ritonavir Versus Triple Combination Therapy of Combivir Plus Saquinavir-SGC/Ritonavir in treatment naive HIV-1 Infected Subjects with High Plasma HIV-1 RNA Levels and Low CD4 Cell Count
WE066, EPI40007 IV The Antiretroviral Pregnancy Registry (APR, Registry)
AZL30002 TRIZAL III A Phase IIIb, Randomised, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of a Triple Combination Tablet (Trizivir) [abacavir, lamivudine, zidovudine] Versus Continued Antiretroviral Triple Therapy in HIV-1 Infected Subjects with Undetectable Plasma HIV-1 RNA Levels (TRIZAL)
AZL30004 III A Phase IIIb/IV, Randomised, Open-Label, Multicentre Study to Evaluate the Efficacy, Safety and Tolerability of TRIZIVIR plus Efavirenz (Quad) Over 72 Weeks Versus Quad Therapy for 48 Weeks Followed by TRIZIVIR Alone for 24 Weeks Versus Quad Therapy for a minimum of 24 Weeks Followed by TRIZIVIR Alone for 48 Weeks in HIV - Infected Antiretroviral Therapy Naïve Adults.
AZL30004 (Extension Phase) III A Phase IIIb/IV, Randomised, Open-Label, Multicentre Study to Evaluate the Efficacy, Safety and Tolerability of TRIZIVIR. plus Efavirenz (Quad) Over 72 Weeks Versus Quad Therapy for 48 Weeks Followed by TRIZIVIR Alone for 24 Weeks Versus Quad Therapy for a minimum of 24 Weeks Followed by TRIZIVIR Alone for 48 Weeks in HIVInfected Antiretroviral Therapy Naïve Adults: Final 168 Week Analysis (Extension Phase).
AZLF 3002 III Multicentre, open-label, pilot study to evaluate the efficacy and safety of a triple therapy combining AZT/3TC/ABC as a combined tablet of TrizivirÒ, in HIV-infected patients with an undetectable viral load after quadruple therapy (COM, ABC, EFV) during CNAF 3008 study (La Francilienne).
AZLF 3003 III A Pilot, Multicentre Study to Evaluate the Efficacy and Safety of an Antiretroviral Therapy with Trizivir [abacavir, lamivudine, zidovudine] and Efavirenz after a 14-week Structured Antiretroviral Treatment Interruption, in HIV-1 Infected Subjects with a Viral Load > 5000 copies/mL and a Total CD4 Count > 300/mm3
AZLF 3006 III An open label study to evaluate long term (96 weeks) safety and efficacy of switch to TRIZIVIR after first line quadruple induction therapy: AZLF 3006 – Suburbs 2
AZLF3004 III An Open-label study to evaluate long-term (48 weeks) safety and efficacy of switch to TRIZIVIR after first line quadruple induction therapy: AZLF3004-Trisud
CNAF3007-Ecureuil III An open label, randomised study, to evaluate the safety and efficacy of CombivirÔ plus abacavir (ZiagenÔ) versus CombivirÔ plus ViraceptÔ, in HIV-1 infected antiretroviral therapy naive adults with a plasma HIV-1 RNA between 1000 and 500,000 copies /mL.
CNAF3016-MULTISUD III A Pilot Study to assess the Efficacy and Safety of a quadritherapy with Combivirä, Abacavirä, Nelfinavirâ switching from week 16 to (TZV) ä, Nelfinavirâ for Antiretroviral Therapy in HIV-infected Naive Subjects with a viral load > 50 000 copies/mL
COL40263 III A Pilot, Open-Label, Multi-Center Study to Evaluate the Efficacy and Safety of a Once-Daily Regimen of Trizivir in Combination with Tenofovir Disoproxil Fumarate in Antiretroviral Therapy-Naïve Subjects with Viral Loads =30,000 copies/mL
ESS40005 III A Phase IIIB Randomized, Multi-center Study of the Efficacy and Safety of COMBIVIR 1 Tablet PO BID Plus ZIAGEN 300mg PO BID Versus an Abacavir 300mg/Lamivudine 150mg/Zidovudine 300mg Combination Tablet PO BID, Administered for 24 Weeks in Subjects With HIV-1 Infection
NZTA4006 III A Phase IIIB, Open-Label, Randomized Study of the Effect of an Education Intervention on Virologic Outcomes, Adherence, Immunologic Outcome, and Health Outcomes in HIV-Infected Subjects from Under-Represented Populations Treated with Triple Nucleoside Therapy (COMBIVIR, Lamivudine 150mg/Zidovudine 300mg, PO BID Plus Abacavir 300 PO BID), for Twenty-four Weeks
AZL10001 I An Evaluation of the Bioequivalence of a Combined Formulated Tablet (300/150/300mg abacavir/lamivudine/zidovudine) Compared to ZIAGEN (abacavir) 300mg tablet, EPIVIR (lamivudine) 150mg tablet, and RETROVIR (zidovudine) 300mg tablet Administered Concurrently and the Effect of Food on Absorption in Healthy Volunteers
AZL10002 I An Evaluation of the Steady-State Pharmacokinetics of abacavir, lamivudine, and zidovudine following administration of a Combined Formulated Tablet (300/150/300mg abacavir/lamivudine/zidovudine) versus ZIAGEN (300mg abacavir) and COMBIVIR (150/300mg lamivudine/zidovudine) in Subjects with HIV-1 Infection.